Personal Finance

Jounce Therapeutics Gets Throttled, Loses 35% Today

A man in dress clothes sits on the ground, holding his head in his hands, in front of a big monitor displaying a declining stock share price.

What happened

Investors were hoping that when an abstract for presentation at the upcoming American Society of Clinical Oncology was released today, it would show robust efficacy for JTX-2011, Jounce Therapeutics ' (NASDAQ: JNCE) lead drug candidate. Unfortunately, the data underwhelmed investors, sparking a steep sell-off that wiped out 35.2% of the company's market value on Thursday.

So what

In collaboration with Celgene Corp. (NASDAQ: CELG) , Jounce has JTX-2011 in phase 2 studies as a monotherapy and in combination with Opdivo for the treatment of various solid tumor cancers, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, and gastric cancer.

A man in dress clothes sits on the ground, holding his head in his hands, in front of a big monitor displaying a declining stock share price.

IMAGE SOURCE: GETTY IMAGES.

In March, Jounce Therapeutics revealed it had submitted some trial data, including one efficacy assessment, for presentation at ASCO; today, those results were unveiled.

Specifically, as of Jan. 27, one out of seven gastric cancer patients had a partial response, and two out of five patients with triple negative breast cancer had stable disease after JTX-2011 monotherapy. In the combination cohort, there were two partial responses and two patients with stable disease out of 19 patients. Also, one out of 15 triple negative breast cancer patients had a partial response.

Now what

Jounce Therapeutics believes the data confirm that JTX-2011 has anti-tumor effects, but clearly, investors were less than impressed by the readout.

It remains to be seen, however, how the data will mature across the entire patient population, and that could make today's sell-off an overreaction. We'll have to wait for more data to parse before we can say for certain that the commercial opportunity for JTX-2011 is dashed. After all, patients in this trial are heavily pre-treated with few treatment options, so any response at all is welcome.

10 stocks we like better than Jounce Therapeutics, Inc.

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Jounce Therapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 8, 2018

Todd Campbell owns shares of Celgene. His clients may have positions in the companies mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

JNCE

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More